| Similar Articles |
|---|
 |
Bio-IT World
August 18, 2004
Mark D. Uehling |
I, Virtual Patient Along with a software company specializing in modeling diseases on the computer, Roche Diagnostics is working on creating a new biomarker for diabetes that could be reduced to a simple blood test.   |
Bio-IT World
May 2006
Kevin Davies |
Trailblazers Test Public Markets Three companies in postgenomic fields are going public. Infinity Pharmaceuticals, Perlegen Sciences, and Entelos announced they would be entering the public markets by means of merger, IPO, and institutional offering. |
The Motley Fool
June 23, 2010
Brian Orelli |
Duo of Diabetes Drug Deals Make J&J Better Licensing deals add to Johnson & Johnson's diabetes franchise. |
The Motley Fool
February 9, 2009
Robert Steyer |
Just Say No to Drug Company Mergers There are some reasons to make a big-pharma deal. But there are as many, if not more, reasons to let these companies pursue smaller deals and collaborations rather than become just another part of a hyphenated corporate name. |
The Motley Fool
March 23, 2009
Brian Orelli |
Which Pharmas Still Have Cash? Pharmaceutical mergers-and-acquisitions activity has been jumping for the past few months, but the consolidation can't go on forever. |
The Motley Fool
December 4, 2008
Brian Orelli |
Drug Deals Require Cash Pharmaceutical companies have been hoarding cash -- patiently waiting for good prices. And it looks like that time has arrived. Take a look at some players in the pharmaceutical field. |
The Motley Fool
October 27, 2009
Brian Orelli |
Pfizer's and Merck's Loss Is These Companies' Gain Are Pfizer and Merck too busy integrating now to take advantage of additional acquisitions? |
The Motley Fool
December 17, 2009
Brian Orelli |
This Acquisition Hears, Smells, and Tastes Soooo Good Johnson & Johnson picks up an ear, nose, and throat medical device maker. |
The Motley Fool
September 28, 2009
Brian Orelli |
The Berkshire of Health Care Johnson & Johnson is becoming the Berkshire Hathaway of health care. In addition to its usual M.O. of bolt-on acquisitions, the health-care giant has recently taken some equity stakes in smaller drug companies. |
Bio-IT World
March 8, 2005
John Russell |
Entelos' Lofty Aspirations This is an interesting period for systems biology's wing of predictive biology companies. The label's luster is fading, but buoyed by pharma's growing interest, they are trying to figure out how to grow. |
The Motley Fool
August 19, 2010
Brian Orelli |
Buffett Is Buying J&J. Should You? It depends on your time horizon. |
Bio-IT World
March 2006
John Russell |
It's All About the Drugs A conversation with biopharma Organon's executive VP for global research and development highlights how, regardless of the company's enthusiasm for new technology, it is first and foremost interested in pharmacology and medicinal chemistry -- drugs. |
The Motley Fool
June 28, 2011
Eric Bleeker |
Johnson & Johnson Is Looking Abroad for Growth Where's Johnson & Johnson generating its sales? |
The Motley Fool
December 24, 2007
Rick Aristotle Munarriz |
4 Stocks That Took a Hike These stocks recently raised their dividends: Pfizer... Eli Lilly... Moody's... Waste Management... |
The Motley Fool
December 18, 2008
Brian Orelli |
Best Stock for 2009: Pfizer Pfizer's languishing stock price has made the company so much more attractive; it could see a breakout in 2009. |
The Motley Fool
November 26, 2010
Brian Orelli |
Get It Together, Johnson & Johnson Another day, another recall. |
Bio-IT World
June 17, 2004
John Russell |
Systems Biology - Now Leaving on Track 1 Entelos, a leader in predictive biosimulation, partners with pharmaceutical and biotech organizations worldwide to develop effective new treatments for disease. Michael French, chief business officer at Entelos, explains what powers the systems biology engine. |
The Motley Fool
October 19, 2011
Brian Orelli |
Not the Best Quarter, but... There's little reason to worry about Johnson & Johnson. |
The Motley Fool
July 12, 2011
Todd Wenning |
What Does Johnson & Johnson Do With Its Free Cash? Johnson & Johnson appears to be making fair use of its free cash flow, and its well-covered dividend may be attractive to income-focused investors. |
The Motley Fool
January 26, 2010
Brian Orelli |
Is the Best of Johnson & Johnson Behind It? Johnson & Johnson announces that its sales fell for the first time in 76 years. |
